Published in Expert Rev Cardiovasc Ther on March 01, 2010
Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest (2012) 1.63
The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol (2011) 1.54
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech (2010) 1.28
Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol (2012) 1.22
Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol (2011) 1.11
Adipose tissue biology and cardiomyopathy: translational implications. Circ Res (2012) 1.05
GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes (2012) 1.03
Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. Curr Pharm Des (2013) 0.99
Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol (2011) 0.95
Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J (2015) 0.82
Impact of weight loss on oxidative stress and inflammatory cytokines in obese type 2 diabetic patients. Afr Health Sci (2016) 0.77
Diabetic cardiomyopathy: is resistin a culprit? Cardiovasc Diagn Ther (2015) 0.77
Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy. Cardiovasc Diabetol (2016) 0.77
Disruption of Nrf2 Synergizes with High Glucose to Cause Heightened Myocardial Oxidative Stress and Severe Cardiomyopathy in Diabetic Mice. J Diabetes Metab (2012) 0.75
Cardiomyocyte GTP Cyclohydrolase 1 Protects the Heart Against Diabetic Cardiomyopathy. Sci Rep (2016) 0.75
Calcium-calmodulin dependent protein kinase mediates the intracellular signaling pathways of cardiac apoptosis in mice with impaired glucose tolerance. J Physiol (2017) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
Exercise capacity and mortality among men referred for exercise testing. N Engl J Med (2002) 14.30
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Mitochondrial dysfunction and type 2 diabetes. Science (2005) 10.25
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell (2000) 10.25
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab (2001) 9.53
Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res (2008) 8.49
The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem (1998) 8.46
Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med (1999) 7.99
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res (2009) 7.09
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest (2000) 7.06
Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell (2009) 6.77
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med (2005) 6.04
Calmodulin kinase II inhibition protects against structural heart disease. Nat Med (2005) 5.87
Stem-cell therapy for cardiac disease. Nature (2008) 5.75
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Diabetes and cardiovascular risk factors: the Framingham study. Circulation (1979) 5.32
A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A (1999) 4.91
New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol (1972) 4.86
Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc Natl Acad Sci U S A (1999) 4.40
Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes (2005) 4.31
Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest (2005) 4.25
Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem (1977) 4.22
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest (2002) 4.22
Lipotoxic diseases. Annu Rev Med (2002) 4.16
Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med (2004) 4.05
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res (1998) 3.87
PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest (2004) 3.86
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev (2004) 3.69
Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest (1967) 3.60
Activation of downstream signals by the long form of the leptin receptor. J Biol Chem (2000) 3.52
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 3.51
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Invited Review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol (1985) (2001) 3.35
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation (2004) 3.28
Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res (2006) 3.27
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation (2005) 3.22
Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation (1999) 3.19
Myocardial cell death in human diabetes. Circ Res (2000) 3.12
Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) (2008) 2.93
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
New drug targets for type 2 diabetes and the metabolic syndrome. Nature (2001) 2.92
Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res (2004) 2.92
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol (2008) 2.91
Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol (2006) 2.80
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev (2007) 2.67
Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation (1997) 2.65
Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension (2004) 2.65
Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab (2001) 2.54
Prospects for stem cell-based therapy. Cell (2008) 2.45
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.30
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation (2007) 2.28
Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol (2002) 2.26
Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res (2003) 2.26
Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab (2003) 2.25
Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest (2007) 2.23
Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation (2001) 2.22
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med (2005) 2.22
Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res (2008) 2.19
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail (2008) 2.09
Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am J Physiol (1993) 2.06
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology (1996) 2.06
Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE (2005) 2.04
Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 2.03
Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res (2007) 2.01
Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation (2003) 2.01
Effects of Na(+)/Ca(2+)-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J Mol Cell Cardiol (2002) 2.00
Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology (2003) 1.99
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol (2006) 1.97
Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations. Am J Physiol Heart Circ Physiol (2008) 1.95
Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens (2003) 1.95
Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circ Res (2001) 1.88
Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 1.87
Expression of mutant p193 and p53 permits cardiomyocyte cell cycle reentry after myocardial infarction in transgenic mice. Circ Res (2004) 1.84
Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes (2007) 1.84
Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res (2005) 1.84
Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes (2002) 1.83
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J (1999) 1.83
Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab (2005) 1.74
Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res (2006) 1.74
Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem (2002) 1.73
Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol (1998) 1.72
Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem (2004) 1.72
Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ Res (2006) 1.71
Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther (2006) 1.71
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab (2004) 1.63
Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc (2009) 1.62
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol (2005) 1.61
Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta (1994) 1.60
Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology (2002) 1.58
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A (2004) 1.77
Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther (2006) 1.71
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol (2011) 1.55
Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol (2007) 1.54
Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol (2008) 1.35
SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther (2010) 1.18
Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med (2008) 1.12
Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol (2006) 1.09
Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc (2013) 1.08
Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem (2011) 1.05
Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc (2012) 1.01
Ventricular arrhythmias after left ventricular assist device implantation. Pacing Clin Electrophysiol (2008) 0.97
KChIP2 attenuates cardiac hypertrophy through regulation of Ito and intracellular calcium signaling. J Mol Cell Cardiol (2010) 0.96
Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol (2011) 0.95
Gene transfer of parvalbumin improves diastolic dysfunction in senescent myocytes. Circulation (2004) 0.94
Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PLoS One (2009) 0.88
In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts. Cardiovasc Res (2005) 0.88
Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. Am J Physiol Heart Circ Physiol (2007) 0.86
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiol (2003) 0.83
Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes. Circulation (2003) 0.81
Na+/Ca2+ exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF-κB pathway. Am J Physiol Heart Circ Physiol (2012) 0.80
Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin. J Physiol (2013) 0.79
Preservation of mechanical and energetic function after adenoviral gene transfer in normal rat hearts. Clin Exp Pharmacol Physiol (2007) 0.77